川超绵阳VS乐山

Atezolizumab plus bevacizumab (Atezo/Bev) is the standard first-line therapy for unresectable hepatocellular carcinoma (uHCC). In the IMbrave150 trial, bevacizumab-related adverse events (AEs) frequently required dose interruption or discontinuation, raising concerns regarding optimal dosing. The effect of initiating therapy with low-dose bevacizumab remains uncertain.

Materials with π-conjugated units usually show strong second-order harmonic generation but excessively large birefringence (Δn), a trade-off intensified by planar restrictions from π-π stacking. Here, we report a monoclinic P2

Prehabilitation and early oral nutrition have been shown to improve postoperative outcomes in colorectal cancer (CRC). However, their combined effects remain unexamined. This study evaluates the effects of a perioperative support (POS) program, integrating prehabilitation and early oral nutrition, on postoperative outcomes in older patients with CRC using propensity score matching (PSM).

The electrocatalytic conversion of NO